
Contents

1	Basic Concepts in Immunology	1
1.1	Natural or Paraspecific Immunity	2
1.2	Acquired or Specific Immunity	3
1.3	Humoral Immunity	3
1.3.1	Immunoglobulin G (IgG)	4
1.3.2	Immunoglobulin M (IgM)	6
1.3.3	Immunoglobulin A (IgA)	6
1.3.4	Immunoglobulin E (IgE)	6
1.3.5	Immunoglobulin D (IgD)	7
1.4	Cell-Mediated Immunity	7
1.5	Immune Response	8
1.6	Cells of the Immune System	9
1.6.1	Lymphoid Channel	9
1.6.2	Myeloid Channel	11
1.7	Cytokines	20
1.7.1	Interferons	20
1.7.2	Interleukins	21
1.7.3	Tumor Necrosis Factor (Cytotoxins)	25
1.7.4	Colony-Stimulating Factor	26
1.7.5	Migration Inhibitory Factor	26
	Further Reading	30
2	Biomarkers of Immunopathology in Veterinary Medicine	31
2.1	Introduction	32
2.2	Specific Cells of the Innate Immune System	33
2.2.1	Neutrophils	33
2.2.2	Monocytes	36
2.2.3	Lymphocytes	37
2.3	Receptors for Microbial Ligands	38
2.3.1	Transmembrane PRRs	39
2.3.2	Cytosolic PRRs	39
2.4	Inflammatory Mediators	39
2.4.1	Cytokines	40

2.4.2	Interleukins	41
2.4.3	Chemokines	41
2.5	Anti-microbial Molecules	42
2.5.1	Complement	42
2.5.2	Lysozyme	42
2.5.3	Anti-microbial Peptides	43
2.5.4	Cathelicidins	43
2.5.5	Defensins	43
2.5.6	Collectins	44
2.6	Conclusion	44
	References	45
3	Hypersensitivity	49
3.1	Hypersensitivity	50
3.2	Type I Hypersensitivity	52
3.2.1	Components of Type I Hypersensitivity	52
3.2.2	Mediators of Type I Hypersensitivity Reaction	57
3.2.3	Clinical Manifestations	58
3.2.4	Detection of Type I Hypersensitivity	63
3.3	Type II Hypersensitivity	64
3.3.1	Mechanism of Type II Hypersensitivity	65
3.3.2	Type II Hypersensitivity to Drugs	72
3.3.3	Type II Hypersensitivity in Infectious Diseases	72
3.4	Type III Hypersensitivity	72
3.4.1	Serum Sickness	74
3.4.2	Autoimmune Complex Disease	76
3.4.3	Arthus Reaction	76
3.4.4	Diseases Associated with Immune Complexes	76
3.4.5	Pathogenesis	77
3.4.6	Clinical Findings	78
3.4.7	Lesions	78
3.5	Type IV Hypersensitivity	81
3.5.1	The Tuberculin Reaction	81
3.5.2	Johnin Reaction	85
3.5.3	Other Intracellular Pathogens Showing DTH	85
3.5.4	Allergic Contact Dermatitis	86
3.5.5	Detection of Type IV Hypersensitivity	86
	Further Reading	87
4	Autoimmunity	89
4.1	General Concept	90
4.2	Mechanism of Induction	91
4.2.1	Physiological Autoimmunity	91
4.2.2	Pathological Autoimmunity	91
4.2.3	Mechanisms of Tissue Injury	95

4.3	Autoimmune Diseases	96
4.3.1	Systemic Autoimmune Diseases	96
4.3.2	Autoimmune Ocular Disease	117
	References	117
	Further Reading	118
5	Immunodeficiency	121
5.1	Immunodeficiency	122
5.1.1	Congenital Immunodeficiency	122
5.1.2	Acquired Immunodeficiency	126
5.2	Diagnosis of Immunodeficiency	138
	Further Reading	139
6	Immunomodulation	143
6.1	Immunomodulation	144
6.2	Need of Immunomodulation	144
6.3	Physiological Products	146
6.3.1	Neuroendocrine Hormones	146
6.4	Neuropeptides	147
6.5	Growth Hormone and Prolactin	149
6.6	Opioid Peptides	149
6.7	Thymic Products	150
6.8	Cytokines	151
6.9	Microbial Products	151
6.9.1	<i>P. acnes</i> (Corynebacterium Parvum)	151
6.10	Lentinan	155
6.11	Probiotics	155
6.12	Chemical Compounds	156
6.12.1	Levamisole	157
6.12.2	Thiabendazole	158
6.12.3	Imuthiol	158
6.12.4	Isoprinosine	158
6.12.5	Indomethacin	158
6.12.6	Ascorbic Acid Derivatives	159
6.12.7	Dihydroheptaprenol	159
6.13	Adjuvants	159
6.14	Herbal Products	161
6.15	Vitamins	165
6.16	Cow Therapy	166
	References	167
7	Immunopathology of Pneumonia in Animals	169
7.1	Introduction	170
7.2	Ruminants	173
7.3	Mycoplasmal Diseases	181
7.4	Peste des Petits Ruminants (PPR)	182

7.5	Chlamydiosis	183
7.6	Parainfluenza-3	183
7.7	Equines	183
7.8	Swine	183
7.9	Porcine Reproductive and Respiratory Syndrome (PRRS)	184
7.10	Swine Influenza	184
7.11	Other Diseases	185
7.12	Small Animals	185
7.13	Immunity to Pneumonia	186
7.14	Innate Immunity	188
7.15	Adaptive Immunity	192
	7.15.1 Humoral Immunity	192
7.16	Cell-Mediated Immunity	193
7.17	Immunodeficiency in Animals	197
	7.17.1 Congenital Immunodeficiency	197
	7.17.2 Acquired Immunodeficiency	198
7.18	Immunomodulation	198
7.19	Evasion Strategies of Microbes	199
7.20	Evasion from Innate Immune Responses	199
	7.20.1 Interference with the Physical Barrier	199
	7.20.2 Interference with Phagocytosis by Predisposing Factors and Pathogens	199
	7.20.3 Effects of Predisposing Factors and Pathogens on the Production of Innate Defense Molecules	200
	7.20.4 Effects on Receptors on the Surface of Airway Epithelial Cells and Cell Signal Transduction	201
	7.20.5 Interference with Intracellular Killing	202
	7.20.6 Interference with IFN System	202
7.21	Evasion of Adaptive Immune Response	203
	7.21.1 Infection of Leukocytes and Suppression of Proliferation	203
	7.21.2 Suppression of Proliferation of Leukocytes	203
	7.21.3 Infection of Cells of the Immune System	203
	7.21.4 Induction of Humoral and Cellular Immune Tolerance	203
	7.21.5 Inhibition of Antibody Activity	204
	7.21.6 Interference with Cytotoxic T-Lymphocyte Response	204
7.22	Conclusion	204
	References	205
8	Immunopathology of the Liver in Animals	217
8.1	Introduction	218
8.2	Anatomy of the Liver	218
8.3	Histology of the Liver	218

8.4	The Bile Duct System and Gallbladder	219
8.5	Cells of the Liver	219
8.6	Blood Supply and Bile Flow	220
8.7	Immunopathology of the Liver	220
8.8	Types and Patterns of Cell Death in the Liver	222
8.9	Necrosis	222
8.10	Apoptosis	225
8.11	Autoimmune Hepatitis (AIH)	226
8.12	Key Inflammatory Pathways in the Development of AIH	226
8.13	Immunopathology of Infectious Diseases Affecting the Liver	227
	8.13.1 Infectious Canine Hepatitis	227
8.14	Wesselsbron Disease	230
8.15	Rift Valley Fever	231
8.16	Lymphoid Leukosis in Poultry	232
8.17	Marek's Disease in Poultry	234
8.18	Leptospirosis	236
8.19	<i>Fusobacterium necrophorum</i>	238
8.20	Trematodes	240
8.21	<i>Cysticercus fasciolaris</i>	244
8.22	<i>Lantana camara</i> toxicity	244
8.23	Conclusion	246
	References	247
9	Immunopathology of Diarrhea in Animals	253
9.1	Introduction	254
9.2	Etiology	255
9.3	Classification of Diarrhea	258
	9.3.1 Acute Diarrhea	259
	9.3.2 Persistent Diarrhea (PD)	259
	9.3.3 Chronic Diarrhea	259
	9.3.4 Small Bowel Diarrhea	259
	9.3.5 Large Bowel Diarrhea	260
	9.3.6 Osmotic Diarrhea	261
	9.3.7 Secretory Diarrhea	261
	9.3.8 Exudative Diarrhea	261
9.4	Pathogenesis of Diarrhea	262
	9.4.1 Bacterial Pathogens of Diarrhea	262
9.5	<i>Escherichia coli</i>	262
9.6	Enteropathogenic <i>E. coli</i> (EPEC)	263
9.7	Enterotoxigenic <i>E. coli</i> (ETEC)	263
9.8	Enterohemorrhagic <i>E. coli</i> (EHEC)	263
9.9	Enteroadherent or Enteroaggregative <i>E. coli</i> (EAEC)	264
9.10	Enteroinvasive <i>E. coli</i> (EIEC)	264
	9.10.1 <i>Shigella</i>	264
	9.10.2 <i>Salmonella</i>	265

9.10.3	<i>Clostridium</i>	266
9.11	Viral Pathogens of Diarrhea	267
9.11.1	Rotavirus	267
9.11.2	Bovine Viral Diarrhea (BVD)	268
9.11.3	Coronavirus	269
9.11.4	Norovirus	269
9.12	Diarrhea due to Intestinal Parasites	270
9.12.1	Giardia	270
9.12.2	<i>Cryptosporidium</i>	271
9.12.3	Trichuris	271
9.12.4	Strongyloides	271
9.12.5	Traveler's Diarrhea (TD)	271
9.13	Chemical Mediators Influencing the Intestinal Motility	272
9.13.1	Serotonin	272
9.13.2	Prostaglandins	272
9.13.3	Claudin	273
9.13.4	Nutrition and Diarrhea	274
9.14	Immunity	276
9.15	Diagnosis	277
9.15.1	Prevention and Prophylaxis	279
9.15.2	Public Health	280
9.16	Conclusion	281
	References	282
10	Immunopathology of Reproductive Disorders of Animals	293
10.1	Introduction	293
10.2	Uterine Function	295
10.3	Innate Immune Defense of the Uterus	296
10.4	Adaptive Immune Defense of the Uterus	298
10.4.1	Humoral Immunity	298
10.4.2	Cell-Mediated Immunity	298
10.5	Anatomical and Physiological Barriers Against Uterine Infections	299
10.6	Prevalence of Uterine Infections	299
10.7	Risk Factors Associated with Uterine Infections	299
10.8	Abortion	300
10.9	Etiology of Abortion	300
10.10	Immunopathology of Abortions	301
10.11	Brucellosis	310
10.12	Mycotic Abortion in Cattle and Sheep	313
10.13	Listeriosis	314
10.14	Trichomoniasis	316
10.15	Neosporosis	320
10.16	Campylobacteriosis	321
10.17	Leptospirosis	324

10.18	Bluetongue Virus	327
10.19	Infectious Bovine Rhinotracheitis	330
10.20	Bovine Herpesvirus 4 Infection	333
10.21	Epizootic/Enzootic Abortions	334
10.22	Toxoplasmosis	337
10.23	Bovine Viral Diarrhea	341
10.24	Equine Viral Arteritis	344
10.25	Conclusion	348
	References	349
11	Immunopathology of Mastitis	373
11.1	Introduction	373
11.2	Mastitis-Causing Pathogens	374
	11.2.1 Bacteria	374
	11.2.2 Viruses	377
11.3	Immune Responses	383
11.4	Host-Pathogen Interactions	384
11.5	Mammary Immunology	385
11.6	Physical and Chemical Barriers of the Teat	385
11.7	Endogenous Defenses	386
11.8	Lactoferrin	386
11.9	Complement	387
11.10	Cytokines	387
11.11	Eicosanoids	388
11.12	Immunoglobulins	389
11.13	Pattern Recognition Receptors (PRRs)	389
11.14	Inflammation	391
11.15	Mammary Vascular Endothelium	391
11.16	Localized Cellular Components of Inflammation	392
	11.16.1 Epithelial Cells	392
	11.16.2 Somatic Cells	393
11.17	Immunopathogenesis	394
11.18	Conclusion	397
	References	398
12	Immunopathological Disorders of Kidneys	405
12.1	Introduction	405
12.2	Glomerulonephritis	406
12.3	Type I Membranoproliferative Glomerulonephritis	406
12.4	Type II Membranoproliferative Glomerulonephritis	409
12.5	Type III Membranoproliferative Glomerulonephritis	410
12.6	Crescentic Glomerulonephritis	410
12.7	IgA Nephropathy	411
12.8	Postinfection Glomerulonephritis	412
12.9	Conclusion	413

References	414
13 Immunopathological Disorders of Joints	417
13.1 Introduction	417
13.2 Normal Cartilage, Joint Capsule, and Synovium	420
13.3 Synovium Function	421
13.4 Rheumatoid Arthritis	422
13.5 Immunopathological Mechanisms of Rheumatoid Arthritis	422
13.6 Immune-Mediated Inflammation in Rheumatoid Arthritis	423
13.7 Role of Interleukin-7 in Immunopathology of Rheumatoid Arthritis	425
13.8 Immune Target Therapy and Ongoing Immune-Modulated Therapy in Rheumatoid Arthritis	425
13.9 Psoriatic Arthritis	426
13.10 Caprine Arthritis Encephalitis Virus-Induced Arthritis	427
13.11 Temporomandibular Joint Destruction (TMJD)	427
13.12 Spondyloarthritis (SpA)	428
13.13 Ankylosing Spondylitis	429
13.14 Summary	430
References	430
14 Immunopathology of Skin Ailments	435
14.1 Introduction	435
14.2 Cellular Components of the Skin	437
14.2.1 Keratinocytes	437
14.2.2 Melanocytes	438
14.2.3 Langerhans Cell	438
14.2.4 Macrophage	441
14.2.5 Mast Cells	441
14.3 Mechanism Regulating Immune-Mediated Skin Injury	441
14.4 Allergic Contact Dermatitis	442
14.5 Pemphigus Foliaceus	443
14.6 Vitiligo	443
14.7 Canine Atopic Dermatitis (CAD)	446
14.8 Flea Allergy Dermatitis (FAD)	446
14.9 Chediak-Higashi Syndrome	447
14.10 Discoid Lupus Erythematosus (DLE)	448
14.11 Conclusion	448
References	449
15 Immunological Interventions for the Management of Coronavirus Disease 2019 (COVID-19)	453
15.1 Introduction	454
15.2 Etiology	455
15.3 Transmission of COVID-19	455
15.4 Predisposing Factors	456

15.5	Clinical Manifestations	457
15.5.1	Pathology	457
15.5.2	Clinical Pathology	458
15.5.3	Diagnosis	459
15.6	Immunological Interventions for the Management of COVID-19	460
15.7	Immunological Interventions	460
15.7.1	Convalescent Plasma Therapy	460
15.7.2	Antagonists of Interleukin 6 Receptor (IL-6R) and IL-6	461
15.7.3	Blockade of the IL-1 Pathway	461
15.7.4	Inhibition of Janus Kinases (JAK)	461
15.7.5	Recombinant Soluble ACE2	462
15.7.6	Inhibition of Granulocyte Macrophage Colony- Stimulating Factor Receptor (GM-CSF-R)	462
15.7.7	Stem Cell Therapy	463
15.7.8	Corticosteroids	463
15.7.9	Remdesivir	463
15.7.10	Chloroquine Phosphate and Hydroxychloroquine	464
15.7.11	Ivermectin	464
15.7.12	Umifenovir (Arbidol)	465
15.7.13	Low Molecular Weight Heparin (LMWH)	465
15.7.14	Nonsteroidal Anti-inflammatory Drugs (NSAIDs)	465
15.7.15	Anticancer Drugs	465
15.7.16	Other Antiviral Compounds	466
15.7.17	CRISPR-Based Tools	466
15.8	Vaccines Against COVID-19	466
15.9	Plant-Based Vaccines to Combat COVID-19	473
15.10	Control Strategies	474
15.11	Role of Artificial Intelligence in Controlling COVID-19 Spread	475
15.12	One Health Approach to Counter Future Pandemics of SARS-CoV-2	475
15.13	Conclusion	476
	References	476
16	Immunopathology of Parasitic Diseases of Animals	483
16.1	Introduction	483
16.2	Innate Immunity Against Parasites	484
16.3	Parasites Recognition	484
16.4	Adaptive Immunity to Parasites	485
16.5	Protozoa Induced Adaptive Immunity	485
16.6	Helminths Induced Adaptive Immunity	486
16.7	Evasion of Immune Responses by Parasites	487
16.8	Trichomoniasis	488

16.9	Neosporosis	489
16.10	Toxoplasmosis	491
16.11	Fasciolosis	493
16.12	<i>Spirocera lupi</i>	495
16.13	<i>Cysticercus fasciolaris</i>	497
16.14	Diarrheal Parasites	499
16.15	Conclusion	499
	References	500
17	Immunopathological Disorders of Cattle and Buffalo	505
17.1	Introduction	506
17.2	Immunodeficiency	507
17.3	Primary Immunodeficiency	507
17.4	Chediak-Higashi Syndrome	507
17.5	Bovine Leukocyte Adhesion Deficiency	508
17.6	Transient Hypogammaglobulinemia	508
17.7	Acquired Immunodeficiency	508
17.8	Bovine Viral Diarrhea Virus	509
17.9	Bovine Immunodeficiency Virus Infection	510
17.10	Bovine Herpes Virus Infection	511
17.11	Hypersensitivity Reactions	511
17.12	Type I Hypersensitivity	513
17.13	Allergic Rhinitis	513
17.14	Acute Systemic Anaphylaxis	513
17.15	Milk Allergy	514
17.16	Insect Bite Allergy	514
17.17	Type II Hypersensitivity	514
17.18	Hemolytic Disease of Newborn Calf	515
17.19	Type III Hypersensitivity	515
17.20	Serum Sickness	516
17.21	Arthus Reaction	517
17.22	Immune Complex-Mediated Glomerulonephritis	517
17.23	Type IV Hypersensitivity	517
17.24	Tuberculin Reaction	518
17.25	Johnin Reaction	519
17.26	Allergic Contact Dermatitis	520
17.27	Autoimmunity	520
17.28	Vitiligo	521
17.29	Conclusion	521
	References	521
18	Immunopathological Disorders in Sheep, Goat, Wild Animals, and Laboratory Animals	525
18.1	Introduction	526

18.2	Hypersensitivity Reactions in Sheep, Goat, Wild Animals, and Laboratory Animals	527
18.3	Type I Hypersensitivity	527
18.4	Acute Systemic Anaphylaxis	527
18.5	Allergic Rhinitis	528
18.6	Type II Hypersensitivity	528
18.7	Blood Groups	529
	18.7.1 Sheep	529
	18.7.2 Goat	529
18.8	Blood Transfusion Reaction	529
18.9	Hemolytic Diseases	530
18.10	Type III Hypersensitivity	530
18.11	Sheep	530
18.12	Rabbit	531
18.13	Type IV Hypersensitivity	531
18.14	Immunodeficiency in Sheep, Goat, Wild Animals, and Laboratory Animals	533
18.15	Primary Immunodeficiency/Congenital Immunodeficiency	533
18.16	Severe Combined Immunodeficiency Disease (SCID)	533
18.17	Transient Hypogammaglobulinemia in Lamb	534
18.18	Secondary Immunodeficiency/Acquired Immunodeficiency	534
18.19	Bluetongue Disease	534
18.20	Border Disease	535
18.21	Jaagsiekte Disease	535
18.22	Feline Leukemia Virus	536
18.23	Mouse Mammary Tumor Virus	536
18.24	Feline Immunodeficiency Virus	536
	18.24.1 Simian Immunodeficiency Virus Infection	536
	18.24.2 Murine Leukemia Virus	537
18.25	Autoimmunity	537
18.26	Pemphigus Foliaceus	537
18.27	Autoimmune Hemolytic Anemia (AIHA)	537
18.28	Orf-Induced Autoimmunity	538
18.29	Johne’s Disease	538
18.30	Autoimmune Disease in a Polar Bear	538
18.31	Conclusion	538
	References	539
19	Immunopathological Disorders in Swine and Equine	543
19.1	Introduction	544
19.2	Hypersensitivity	544
19.3	Type I Hypersensitivity	544
19.4	Pathogenesis of Type I Hypersensitivity	545
19.5	Clinical Manifestation of Type I Hypersensitivity	546
	19.5.1 Diagnosis	548

19.6	Type II Hypersensitivity and Its Pathogenesis	548
19.7	Clinical Manifestation of Type II Hypersensitivity Reaction . . .	548
19.7.1	Diagnosis	550
19.8	Type III Hypersensitivity and Its Pathogenesis	550
19.8.1	Clinical Manifestation of Type III Hypersensitivity Reaction	550
19.8.2	Diagnosis	551
19.9	Type IV Hypersensitivity and Its Pathogenesis	551
19.9.1	Clinical Manifestation of Type IV Hypersensitivity Reaction	552
19.9.2	Diagnosis	552
19.10	Immunodeficiency Diseases	552
19.11	Primary Immunodeficiency Diseases	553
19.11.1	Secondary Immunodeficiency Diseases	554
19.12	Autoimmune Disorders	555
19.13	Clinical Manifestation of the Autoimmune Disorders	555
19.14	Conclusion	558
	References	558
20	Immunopathological Disorders of Pet Animals	563
20.1	Introduction	563
20.2	Immunopathology	564
20.3	Types of Hypersensitivity	564
20.4	Disease Related to Type 1 Hypersensitivity	564
20.4.1	Anaphylactic Shock	564
20.4.2	Urticaria and Angioedema	565
20.4.3	Canine Atopic Dermatitis	565
20.4.4	Flea Allergy Dermatitis (Flea Bite Hypersensitivity)	565
20.5	Type 2 Hypersensitivity	566
20.6	Disease Related to Type 2 Hypersensitivity	566
20.6.1	Incompatible Blood Transfusion	566
20.7	Type 3 Hypersensitivity	566
20.8	Disease Related to Type 3 Hypersensitivity	568
20.8.1	Serum Sickness	568
20.8.2	Arthus Reaction	568
20.8.3	Glomerulonephritis	568
20.8.4	Type 4 Hypersensitivity	568
20.9	Disease Related to Type 4 Hypersensitivity	569
20.9.1	Allergic Contact Dermatitis	569
20.10	Autoimmune Diseases	570
20.11	Autoimmune Diseases of the Pet Animals	570
20.11.1	Systemic Lupus Erythematosus	570
20.11.2	Rheumatoid Arthritis	570
20.11.3	Autoimmune Thyroiditis	571

20.11.4	Myasthenia Gravis	571
20.12	Immunodeficiency	571
20.13	Disorder Related to Primary Immunodeficiency	572
20.13.1	Severe Combined Immunodeficiency Syndrome (SCID)	572
20.13.2	Lethal Acrodermatitis	572
20.13.3	Chediak-Higashi Syndrome	572
20.14	Disorder Related to Secondary Immunodeficiency	572
20.14.1	Canine Parvovirus Infection	572
20.14.2	Canine Distemper	573
20.14.3	Drug Therapy Defects	573
	References	573
21	Techniques in Immunopathology	577
21.1	Collection of Blood and Serum	578
21.2	Leucocyte Count	579
21.2.1	Total Leucocyte Count (TLC)	579
21.2.2	Differential Leucocyte Count (DLC)	580
21.2.3	Absolute Lymphocyte Count (ALC)	580
21.2.4	Absolute Neutrophil Count (ANC)	581
21.3	Collection of Lymphoid Cells	583
21.3.1	Blood	583
21.3.2	Prescapular Lymph Node	584
21.3.3	Mesenteric Lymph Nodes	584
21.3.4	Mucosa-Associated Lymphoid Tissue (MALT)	584
21.3.5	Respiratory-Associated Lymphoid Tissue (RALT)	585
21.3.6	Spleen	586
21.4	Lymphocyte Blastogenesis Assay	586
21.5	Macrophage Function Test	587
21.5.1	Nitroblue Tetrazolium Test	587
21.5.2	Bactericidal Activity	588
21.6	Delayed-Type Hypersensitivity (DTH) Reaction	588
21.6.1	Allergens	589
21.6.2	Tuberculin Test	589
21.6.3	Johnin Test	589
21.6.4	Mallein Test	590
21.6.5	DNCB-/DNFB-Induced DTH Reaction	590
21.7	Gamma Globulins in Serum	592
21.8	Measurement of Antibody Titer	594
21.8.1	Enzyme-Linked Immunosorbent Assay (ELISA)	594
21.9	Dot Immunobinding Assay (DIA)	597
21.10	Agglutination Test	599
21.11	Immunofluorescence Techniques	599
21.11.1	Direct Method	600
21.11.2	Indirect Method	600

21.12	Immunoperoxidase Techniques (IPT)	600
21.12.1	Antigen Detection	602
21.12.2	Enumeration of T and B Cells	605
21.13	Peroxidase Antiperoxidase (PAP) Techniques	607
21.14	Avidin-Biotin Complex Techniques	609
21.14.1	Enzyme-Labeled Avidin-Biotin Method	610
21.14.2	Bridged Avidin-Biotin Method	610
21.14.3	Avidin-Biotin Complex Method	610
21.15	Detection of Immune Complex	611
21.15.1	Kidneys	611
21.15.2	Serum	615
21.16	Microscopic Evaluation of Lymphoid Organs	615
21.16.1	Processing of Tissues	615
21.16.2	Staining	618
21.17	Evaluation of Xenobiotics	619
21.17.1	Humoral Immune Response	619
21.17.2	Cell-Mediated Immune Response	620
	References	621
22	Molecular Biology Techniques of Pivotal Importance in Veterinary	
	Diagnosics	623
22.1	Polymerase Chain Reaction (PCR)	624
22.1.1	Principle	624
22.1.2	Ingredients	624
22.1.3	Primers	625
22.2	Taq DNA Polymerase	625
22.2.1	Three Stages in PCR	625
22.2.2	Applications of PCR	626
22.3	Microarray	627
22.3.1	Principle	627
22.3.2	Types of Microarrays	627
22.3.3	DNA Microarray	628
22.3.4	Applications of Microarrays	628
22.4	Lateral Flow (Immuno) Assay	628
22.4.1	Principle	628
22.4.2	Parts of LFA Device	628
22.4.3	Material of the Sample Pad	630
22.4.4	Optimization	631
22.4.5	Diagnostic Applications	631
22.4.6	Advantages of LFA	631
22.5	Complement Fixation Test	631
22.5.1	Principle	632
22.5.2	Procedure	632
22.5.3	Interpretation of Results	632
22.5.4	Detection of Antigen	633

22.5.5	Quantitative Testing	633
22.5.6	Applications of CFT	633
22.6	High-Performance Liquid Chromatography (HPLC)	634
22.6.1	Principle	634
22.6.2	Types of HPLC	634
22.6.3	Procedure	635
22.6.4	Applications of HPLC	636
22.7	Confocal Microscopy	636
22.7.1	Principle	636
22.7.2	Applications of Confocal Microscope	637
22.7.3	Advantages of Confocal Microscopy	638
22.7.4	Cons of Confocal Microscope	638
22.8	Fluorescence-Activated Cell Sorting (FACS)	638
22.8.1	Principle	638
22.8.2	Mechanism of FACS	639
22.8.3	Procedure	639
22.8.4	Quantifying the FACS Data	640
22.8.5	Clinical Applications	642
22.9	CRISPR/Cas9 Technology	642
22.9.1	CRISPR as the Genome-Editing Technology	642
22.9.2	Different CRISPR Systems and Their Uses in Genome Editing	643
22.9.3	Utilizing CRISPR-Cas9 Beyond Genome Editing	644
22.10	Conclusion	644
	References	645